Epizyme (NASDAQ:EPZM) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

EPZM has been the topic of a number of other reports. ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Roth Capital began coverage on shares of Epizyme in a research report on Thursday, February 1st. They set a “buy” rating and a $24.00 target price on the stock. Oppenheimer set a $26.00 target price on shares of Epizyme and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Zacks Investment Research cut shares of Epizyme from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, SunTrust Banks reissued a “buy” rating and set a $27.00 target price on shares of Epizyme in a research report on Wednesday. Two analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $23.33.

How to Become a New Pot Stock Millionaire

Epizyme (NASDAQ:EPZM) opened at $19.65 on Thursday. The firm has a market cap of $1,360.00, a P/E ratio of -15.12 and a beta of 2.00. Epizyme has a 12-month low of $9.30 and a 12-month high of $21.40.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.05. The business’s revenue was down 100.0% on a year-over-year basis. research analysts predict that Epizyme will post -2.23 EPS for the current fiscal year.

In other news, COO Matthew Ros sold 72,264 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $16.63, for a total transaction of $1,201,750.32. Following the transaction, the chief operating officer now directly owns 74,867 shares of the company’s stock, valued at $1,245,038.21. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 25.20% of the company’s stock.

Several large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its stake in shares of Epizyme by 3.3% in the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after buying an additional 1,068 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Epizyme by 2.6% in the fourth quarter. TIAA CREF Investment Management LLC now owns 112,844 shares of the biopharmaceutical company’s stock worth $1,416,000 after buying an additional 2,832 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Epizyme by 2.6% in the third quarter. Bank of New York Mellon Corp now owns 202,178 shares of the biopharmaceutical company’s stock worth $3,852,000 after buying an additional 5,140 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of Epizyme by 12.6% in the third quarter. New York State Common Retirement Fund now owns 46,600 shares of the biopharmaceutical company’s stock worth $888,000 after buying an additional 5,200 shares during the last quarter. Finally, American International Group Inc. increased its stake in shares of Epizyme by 19.3% in the fourth quarter. American International Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock worth $414,000 after buying an additional 5,334 shares during the last quarter. Institutional investors and hedge funds own 86.09% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Epizyme (EPZM) Lifted to “Buy” at BidaskClub” was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/03/15/epizyme-epzm-lifted-to-buy-at-bidaskclub.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.